PD-1 Resistant Head and Neck Cancer (HNC) Market

DelveInsight’s ‘PD-1 Resistant Head and Neck Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of and historical and forecasted epidemiology as well as the market trends of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.

The PD-1 Resistant Head and Neck Cancer market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted PD-1 Resistant Head and Neck Cancer symptoms market size from 2018 2030 segmented by the major markets. The report also covers current PD-1 Resistant Head and Neck Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China
• South Korea
• Taiwan

Study Period: 2018–2030

PD-1 Resistant Head and Neck Cancer Disease Understanding and Treatment Algorithm

PD-1 Resistant Head and Neck Cancer Overview

Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease encompassing various tumors that originate in the hypopharynx, oropharynx, lip, oral cavity, nasopharynx, or larynx. The disease group as a whole is associated with different epidemiology, etiology, and therapy. Worldwide, it represents the sixth most common neoplasia and accounts for 6% of all cases, being responsible approximately for 1–2% of tumor deaths.

The three main types of treatment for managing head and neck cancer were radiation therapy, surgery, and chemotherapy. However, the survival rate for head and neck cancer is quite low due to its ability to evade the immune response. Immune escape and T cell exhaustion are mechanisms used by Head and Neck cancer for cancer survival in the tumor microenvironment. Several immune checkpoint inhibitors have been approved for cancer which has significantly improved the survival rate.

PD-1 Resistant Head and Neck Cancer Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the PD-1 Resistant Head and Neck Cancer market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, Japan, China, South Korea, and Taiwan.

The DelveInsight PD-1 Resistant Head and Neck Cancer market report give a thorough understanding of PD-1 Resistant Head and Neck Cancer symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides PD-1 Resistant Head and Neck Cancer symptoms of treatment algorithms and treatment guidelines for PD-1 Resistant Head and Neck Cancer symptoms in the US, Europe, Japan, China, South Korea, and Taiwan.

If a person has symptoms and signs of head and neck cancer, the doctor will take a complete medical history, noting all symptoms and risk factors. During a physical examination, the doctor feels for any lumps on the neck, lips, gums, and cheeks. The doctor will also inspect the nose, mouth, throat, and tongue for abnormalities, often using a light and a mirror for a clearer view. Blood and urine tests may be done to help diagnose cancer. Also, the biopsy may include testing to see whether the person has HPV. As described in Risk Factors and Prevention, HPV has been linked to a higher risk of some head and neck cancers. In some cases, whether a person has HPV can also be a factor in determining which treatments are likely to be most effective.

Due to the inconclusive evidence for available treatment options, the management of RD varies among practitioners. Most RD management is still based on preliminary evidence, and there is great variability in the topical agents and dressings used in practice by radiation oncologists to prevent and treat RD. Regardless of the approach used, PD-1 Resistant Head and Neck Cancer management have two major objectives, prevention of PD-1 Resistant Head and Neck Cancer (Prophylaxis) and treatment of PD-1 Resistant Head and Neck Cancer.

PD-1 Resistant Head and Neck Cancer Epidemiology

The PD-1 Resistant Head and Neck Cancer symptoms-epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for the major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The total incident cases of PD-1 Resistant Head and Neck Cancer are increasing during the study period, i.e., 2018–2030.

The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck cancer diagnosed patients, PD-1 treated patients and PD-1 refractory patients. The report includes PD-1 Resistant Head and Neck Cancer symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan from 2018 to 2030.

Country-wise PD-1 Resistant Head and Neck Cancer Epidemiology

The epidemiology segment also provides the PD-1 Resistant Head and Neck Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan.

The total incident cases of PD-1 refractory patients of PD-1 Resistant Head and Neck Cancer-associated in the mentioned countries was 11,940 in 2020.

PD-1 Resistant Head and Neck Cancer Drug Chapters

The PD-1 Resistant Head and Neck Cancer report’s drug chapter segment encloses the detailed analysis of PD-1 Resistant Head and Neck Cancer’s early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the PD-1 Resistant Head and Neck Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

PD-1 Resistant Head and Neck Cancer Emerging Drug

Monalizumab (IPH2201): AstraZeneca/Innate Pharma

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T-cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies.

Buparlisib: Adlai Nortye Biopharma

Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. Buparlisib significantly inhibited tumor growth in the animal model and showed a dose-response trend in anti-PD-1 refractory tumor-bearing mice. The dose range of buparlisib was consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.

Products detail in the report…

PD-1 Resistant Head and Neck Cancer Market Outlook

The PD-1 Resistant Head and Neck Cancer market outlook helps build a detailed comprehension of the historical, current, and forecasted PD-1 Resistant Head and Neck Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of PD-1 Resistant Head and Neck Cancer market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the PD-1 Resistant Head and Neck Cancer market in the mentioned countries is expected to grow in the study period 2018–2030.

Although ICI is a successful new approach in cancer therapy, these checkpoint inhibitors may also lead to a loss of immune tolerance of healthy tissue, which results in various side effects, referred to as immune-related adverse events (irAEs). According to few references, up to one-fourth of patients on ipilimumab monotherapy and about the same percentage of patients on combined therapy suffer from severe (grade 3 or 4) enterocolitis. According to Burla (2020), overall, 15–25% of patients on single immunotherapy and about 65% of patients on combined immunotherapy suffer from grade 3 or grade 4 irAEs.

Immuno-oncology agents, including immune checkpoint inhibitors (ICIs), have revolutionized the treatment of a range of cancer types. Checkpoint molecules suppress T-cell function through various mechanisms and are exploited by tumor cells to evade the host immune attack. ICIs counteract this immunosuppression and restore immune responses against cancer.

Key Findings

This section includes a glimpse of the PD-1 Resistant Head and Neck Cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.

The market size of PD-1 Resistant Head and Neck Cancer in the major markets was USD 0.0 million in 2020.

The United States Market Outlook

This section provides the total PD-1 Resistant Head and Neck Cancer market size and market size by therapies in the United States.

The United States accounts for the largest market size of PD-1 Resistant Head and Neck Cancer compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, China, South Korea, and Taiwan.

EU-5 Countries: Market Outlook

The total PD-1 Resistant Head and Neck Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in Japan are also mentioned.

China Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in China are also mentioned.

South Korea Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in South Korea are also mentioned.

Taiwan Market Outlook

The total PD-1 Resistant Head and Neck Cancer Market Size and Market Size by therapies in Taiwan are also mentioned.

PD-1 Resistant Head and Neck Cancer Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the PD-1 Resistant Head and Neck Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again help investigate factors important in the market uptake and in making financial and regulatory decisions.

PD-1 Resistant Head and Neck Cancer Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses PD-1 Resistant Head and Neck Cancer’s key players involved in developing targeted therapeutics.

Major players include AstraZeneca/Innate Pharma, Adlai Nortye Biopharma, Rakuten Medical, Kymab Limited, and Debiopharm International SA.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for PD-1 Resistant Head and Neck Cancer emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs’ and SMEs’ opinions working in the PD-1 Resistant Head and Neck Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or PD-1 Resistant Head and Neck Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the PD-1 Resistant Head and Neck Cancer Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of PD-1 Resistant Head and Neck Cancer, explaining its causes, signs and symptoms, physiology, and currently available therapies.
• Comprehensive insight has been provided into the PD-1 Resistant Head and Neck Cancer epidemiology and treatment in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
• Additionally, an all-inclusive account of both the current and emerging therapies for PD-1 Resistant Head and Neck Cancer is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• A detailed review of the PD-1 Resistant Head and Neck Cancer market, historical and forecasted, is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global PD-1 Resistant Head and Neck Cancer market.

Report Highlights

• In the coming years, the PD-1 Resistant Head and Neck Cancer market is set to change due to the rising awareness of the disease and the favorable environment for new anti-infective modalities, expanding the market’s size to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Resistant Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for PD-1 Resistant Head and Neck Cancer. The launch of emerging therapies will significantly impact the PD-1 Resistant Head and Neck Cancer market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

PD-1 Resistant Head and Neck Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• PD-1 Resistant Head and Neck Cancer Pipeline Analysis
• PD-1 Resistant Head and Neck Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

PD-1 Resistant Head and Neck Cancer Report Key Strengths

• 10-years Forecast
• The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan Coverage
• PD-1 Resistant Head and Neck Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

PD-1 Resistant Head and Neck Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the PD-1 Resistant Head and Neck Cancer market share (%) distribution in 2018, and how would it look in 2030?
• What would be the PD-1 Resistant Head and Neck Cancer total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
• What are the market’s key findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan, and which country will have the largest PD-1 Resistant Head and Neck Cancer market size during the study period (2018–2030)?
• At what CAGR, the PD-1 Resistant Head and Neck Cancer market is expected to grow by the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
• What would be the PD-1 Resistant Head and Neck Cancer market outlook across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?
• What would be the PD-1 Resistant Head and Neck Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of PD-1 Resistant Head and Neck Cancer?
• What is the historical PD-1 Resistant Head and Neck Cancer patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
• What would be the forecasted patient pool of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
• What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan concerning the patient population about PD-1 Resistant Head and Neck Cancer?
• Out of all the countries, which country would have the largest incident PD-1 Resistant Head and Neck Cancer population during the study period (2018–2030)?
• At what CAGR is the population expected to grow by the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan during the study period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of PD-1 Resistant Head and Neck Cancer along with the approved therapy?
• What are the current treatment guidelines for the treatment of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan?
• What are the PD-1 Resistant Head and Neck Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, and safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of PD-1 Resistant Head and Neck Cancer?
• How many therapies are developed by each company for the treatment of PD-1 Resistant Head and Neck Cancer?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of PD-1 Resistant Head and Neck Cancer?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to PD-1 Resistant Head and Neck Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for PD-1 Resistant Head and Neck Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for PD-1 Resistant Head and Neck Cancer?
• What are the global historical and forecasted markets of PD-1 Resistant Head and Neck Cancer?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the PD-1 Resistant Head and Neck Cancer market.
• To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, South Korea, and Taiwan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the PD-1 Resistant Head and Neck Cancer market.
• To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market.